NASDAQ:CELU Celularity (CELU) Stock Price, News & Analysis → The Tesla Indicator Is Bullish (From WealthPress) (Ad) Free CELU Stock Alerts $3.37 -0.09 (-2.60%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$3.17▼$3.5050-Day Range$2.95▼$5.5452-Week Range$1.59▼$8.90Volume18,906 shsAverage Volume30,235 shsMarket Capitalization$65.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Celularity alerts: Email Address Ad DTIREPLAY AVAILABLE: $0.25 Cent TradesRecently, I revealed how my new $0.25 Cent Trades works… If you didn’t see it, here’s the deal… As long as the $0.25 Cent Trades are set the day before some predetermined dates my team and I found… Well, that’s when the magic happens…Click now to see for yourself what $0.25 Cent Trades is all about About Celularity Stock (NASDAQ:CELU)Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Read More CELU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELU Stock News HeadlinesMay 24, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingMay 22, 2024 | americanbankingnews.comCelularity (NASDAQ:CELU) Trading 2.5% Higher May 14, 2024 | globenewswire.comCelularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyApril 22, 2024 | globenewswire.comCelularity Inc. to Host Investor and Analyst Research & Development DayApril 19, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingApril 18, 2024 | globenewswire.comCelularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024April 15, 2024 | globenewswire.comCelularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsApril 8, 2024 | globenewswire.comCelularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsMarch 26, 2024 | finance.yahoo.comCelularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LMarch 20, 2024 | finanznachrichten.deCelularity Inc.: Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 20, 2024 | markets.businessinsider.comCelularity Announces Submission Of Request For Orphan Drug Designation For PDA-002March 20, 2024 | globenewswire.comCelularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 16, 2024 | finance.yahoo.comCELU Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comCELU Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comCelularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 14, 2024 | globenewswire.comCelularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 12, 2024 | globenewswire.comCelularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressMarch 8, 2024 | edition.cnn.comCelularity Inc. Class AMarch 7, 2024 | globenewswire.comCelularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsFebruary 24, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Announces 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comStocks to Watch: Intuitive Machines, CelularityFebruary 23, 2024 | markets.businessinsider.comCelularity Announce 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comCelularity to Effect 1-for-10 Reverse Stock SplitFebruary 23, 2024 | globenewswire.comCelularity Announces 1-for-10 Reverse Stock SplitFebruary 22, 2024 | finance.yahoo.comCelularity Inc.'s (NASDAQ:CELU) top owners are public companies with 35% stake, while 35% is held by individual investorsSee More Headlines Receive CELU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today5/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CELU CUSIPN/A CIK1752828 Webwww.celularity.com Phone908-768-2170FaxN/AEmployees225Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$14.19 million Net Margins-1,226.72% Pretax Margin-1,226.64% Return on Equity30.79% Return on Assets13.28% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.14 Sales & Book Value Annual Sales$17.98 million Price / Sales3.63 Cash Flow$1.78 per share Price / Cash Flow1.89 Book Value$13.36 per share Price / Book0.25Miscellaneous Outstanding Shares19,380,000Free Float15,367,000Market Cap$65.31 million OptionableOptionable Beta0.43 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Robert Joseph Hariri M.D. (Age 65)Ph.D., Founder, CEO & Chairman Comp: $1.24MMr. David C. Beers C.F.A. (Age 54)Chief Financial Officer Comp: $455.02kMr. John R. Haines (Age 66)Senior EVP, Global Manager & Chief Administrative Officer Comp: $503.56kRamji KrishnanChief Technology OfficerCarlos RamirezSVP of Investor RelationsMr. Kyle Harold Fletcher Esq. (Age 39)Executive VP, General Counsel & Chief Compliance Officer Dr. Stephen A. Brigido D.P.M. (Age 48)President of Degenerative Diseases Dr. Adrian Kilcoyne M.B.A. (Age 53)M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs Sharmila Koppisetti M.D.Senior Vice President of Clinical Dev. Immunology & Drug SafetyMr. Tim WilkSenior Vice President of Technical OperationsMore ExecutivesKey CompetitorsMicrovastNASDAQ:MVSTATI Physical TherapyNYSE:ATIPCarLotzNASDAQ:LOTZCareMaxNASDAQ:CMAXEnanta PharmaceuticalsNASDAQ:ENTAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 3,348,288 shares on 5/10/2024Ownership: 1.986%HB Wealth Management LLCSold 36,000 shares on 4/30/2024Ownership: 0.124%Kok Thay LimBought 2,141,098 shares on 1/12/2024Total: $5.35 M ($2.50/share)Robert J HaririBought 935,758 shares on 10/5/2023Total: $1.50 M ($1.60/share)Robert J HaririBought 906,453 shares on 9/29/2023Total: $1.54 M ($1.70/share)View All Insider TransactionsView All Institutional Transactions CELU Stock Analysis - Frequently Asked Questions How have CELU shares performed in 2024? Celularity's stock was trading at $2.4740 at the beginning of the year. Since then, CELU shares have increased by 36.2% and is now trading at $3.37. View the best growth stocks for 2024 here. Are investors shorting Celularity? Celularity saw a increase in short interest in May. As of May 15th, there was short interest totaling 627,100 shares, an increase of 5.4% from the April 30th total of 595,000 shares. Based on an average daily trading volume, of 70,000 shares, the short-interest ratio is currently 9.0 days. Approximately 5.9% of the company's stock are sold short. View Celularity's Short Interest. How were Celularity's earnings last quarter? Celularity Inc. (NASDAQ:CELU) released its quarterly earnings results on Friday, November, 12th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of ($3.50) by $7.50. The firm earned $10.62 million during the quarter, compared to the consensus estimate of $3.46 million. Celularity had a negative net margin of 1,226.72% and a positive trailing twelve-month return on equity of 30.79%. When did Celularity's stock split? Celularity's stock reverse split on Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Celularity's major shareholders? Celularity's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.99%), HB Wealth Management LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri. View institutional ownership trends. How do I buy shares of Celularity? Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELU) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.